Bavencio OverviewAvelumab (trade name Bavencio) is a fully human monoclonal antibody developed by Merck KGaA and Pfizer and Eli Lilly and Company in Canada as a pharmaceutical drug for use in immunotherapy, originally for the treatment of non-small-cell lung carcinoma (NSCLC). Avelumab targets the protein programmed death-ligand 1 (PD-L1). It has received orphan drug designation by the European Medicines Agency for the treatment of gastric cancer in January 2017. The US Food and Drug Ad...
Read more Bavencio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Avelumab
Recent Bavencio Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 20mg/ml
NDC Database Records for Bavencio: (1 result)Sorted by National Drug Code
- 44087-3535 Bavencio 20 mg/ml Intravenous Injection, Solution, Concentrate by Emd Serono, Inc.